Overcoming the challenges of drug development in platinum-resistant ovarian cancer

Overcoming the challenges of drug development in platinum-resistant ovarian cancer

The definition of “platinum-resistant ovarian cancer” has evolved; it now also reflects cancers for which platinum treatment is no longer an option. Standard of care for platinum-resistant ovarian cancer is single-agent, non-platinum chemotherapy with or without bevacizumab, which produces modest re...

Full description

Bibliographic Details
Main Authors: Ramez N. Eskander, Kathleen N. Moore, Bradley J. Monk, Thomas J. Herzog, Christina M. Annunziata, David M. O’Malley, Robert L. Coleman
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Oncology
Subjects:
bevacizumab
biomarker
folate receptor alpha
mirvetuximab soravtansine
platinum-resistant ovarian cancer
and targeted therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1258228/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1258228/full

Similar Items